Official Journals By StatPerson Publication


Abstract  Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the eye) due to allergy. The conjunctiva is a thin membrane that covers the eye. When an allergen irritates the conjunctiva, common symptoms that occur in the eye include: ocular itching, eyelid swelling, tearing, photophobia, watery discharge, and foreign body sensation. The cause of allergic conjunctivitis is an allergic reaction of the body's immune system to an allergen. Allergic conjunctivitis is common in people who have other signs of allergic disease such as hay fever, asthma and eczema. Among the most common allergens that cause conjunctivitis are Pollen from trees, grass and ragweed, Animal skin and secretions such as saliva, Perfumes, Cosmetics and someskin medicines. Aims and Objectives: To study the effect of Diclofenac Sodium with That of Ketorolac Tromethamine Ophthalmic Solution in the treatment of Allergic Conjunctivitis. Methodology: After approval from Institutional Ethical Committee, a prospective clinical trial in the 70 patients was carried out. Patients having symptoms of Allergic Conjunctivitis were informed about both these treatment modalities and effectiveness and limitations. After having consent of the patients; they were included into the study. All the Patients were given treatment first time and those who were having history of use of any drugs e.g.Like steroids used in past were excluded from the study. Patients were given treatment randomly by Diclofenac (0.5%) and Ketorolac (0.1%) by computer generated random numbers. All the patients were evaluated by physician using a scales scores at baseline (day 0), mid-week (day 3), day 7 and day 14 after the initiation of the therapy. At each visit, the signs and symptoms were rated by the physician using a scale from 0-3(mild-1, moderate-2, and severe-3). Result: The mean age in Diclofenac group was 17±3.4 Yrs. And in Ketorolac group was 18± 4.2 Yrs. There were 25 Males and 10 Females in Diclofenac group and 27 Males and 8 Females in Ketorolac group. Mean duration of Disease in both the groups were 2.9±2.1 Months. And 3.1±2.5 Months respectively in Diclofenac and Ketorolac group all these characteristics are comparable to each other. Ocular-itching, Burning sensation, Discharge, Photophobia, Foreign body sensation, Swollen eye all these characters were compared in Diclofenac and Ketorolac group at Baseline, at Day -3, Day-7, Day14 by Physicians scale score were significantly lower in the Diclofenac group and Ketorolac group at all the three times (P<0.05;Unpaired t-test was used for statistical analysis. Conclusion: Use of either Diclofenac or Ketorolac; both of them reduces symptoms of allergic conjunctivitis drastically, but the reduction of symptoms were significantly more marked–– in Diclofenac group as compared to the ketorolac group so topical use of Diclofenac is better than Ketorolac in the management of Allergic conjunctivitis.

Key words: Allergic Conjunctivitis (AC), Diclofenac Sodium, Ketorolac Tromethamine.


STATPERSON PUBLISHING GROUP | Aurangabad | Maharashtra |2016 | INDIA
© Copyright 2016 Statperson Publishing Corporation. a division of Statperson Consultancy.
All Rights Reserved.